Multiple myeloma - bortezomib, lenalidomide and pomalidomide

The PBS subsidises bortezomib, lenalidomide and pomalidomide for patients with multiple myeloma.

Patient eligibility

Treatment with bortezomib can be subsidised through the PBS under the National Health Act 1953, Section 100 Arrangements - Efficient Funding of Chemotherapy (EFC), for a patient with multiple myeloma.

Treatment with lenalidomide and pomalidomide can be subsidised through the PBS under the National Health Act 1953, Section 100 Arrangements - Highly Specialised Drug (HSD) Program, for a patient with multiple myeloma.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits outlines restrictions for prescribing bortezomib, lenalidomide and pomalidomide.

Section 100 arrangements - lenalidomide and pomalidomide 

These items are available for day admitted patients, non-admitted patients, or patients on discharge who are attending:

  • an approved private hospital
  • a participating public hospital, or
  • a public hospital

These items are not PBS subsidised for hospital in-patients.  You must include the hospital name and provider number on the authority application form.

Bortezomib

Initial treatment - newly diagnosed

Make all initial applications for authority approval to prescribe bortezomib for the treatment of newly diagnosed multiple myeloma in writing and:

All applications must include the completed:

Initial treatment of progressive disease and retreatment

Make all initial applications for authority approval to prescribe bortezomib for the initial treatment of progressive multiple myeloma including retreatment in writing and:

Initial applications must include the completed:

Continuing treatment - newly diagnosed

Newly diagnosed patients who are ineligible for high-dose chemotherapy

Call the PBS Complex Drugs Programs enquiry line to make an application for continuing treatment for patients who don't have progressive disease and haven't yet achieved a best confirmed response to bortezomib.

Continuing PBS subsidised treatment won't be approved if there’s a gap of more than 6 months between the initial application and this application.

Newly diagnosed patients with severe acute renal failure

Fax the PBS Complex Drugs Program to make an application for continuing treatment for patients who remain in renal failure and can demonstrate at least a partial response to bortezomib.

Complex Drugs Program staff will then contact you by phone.

Continuing PBS subsidised treatment won't be approved if there’s a gap of more than 6 months between the initial application and this application.

Make all applications for continuing authority approval to prescribe bortezomib for the treatment of multiple myeloma, for severe acute renal failure, in writing and:

Continuing applications must include the completed:

Continuing treatment - progressive disease and retreatment

Make all applications for continuing authority approval to prescribe bortezomib for the treatment of multiple myeloma in writing and:

Continuing applications must include the completed:

Beyond 4 cycles, continuing PBS subsidised treatment won't be approved if there's a gap of more than 6 months between the initial and the subsequent application.

Beyond 8 cycles, continuing PBS subsidised treatment won't be approved if there's a gap of more than 10 months between the initial application and an application after the completion of 8 treatment cycles.

Lenalidomide

Initial treatment - newly diagnosed

Patients receiving lenalidomide under this PBS listing must be registered in the i-access risk management program. Read more on the Celgene website or call Celgene on 1800 235 436.

Make all initial applications for authority approval to prescribe lenalidomide for the treatment of newly diagnosed multiple myeloma in writing and:

Initial applications must include the completed:

Initial treatment - progressive disease

Patients receiving lenalidomide under this PBS listing must be registered in the i-access risk management program. Read more on the Celgene website or call Celgene on 1800 235 436.

Make all initial applications for authority approval to prescribe lenalidomide for the treatment of progressive multiple myeloma in writing and:

Initial applications must include the completed:

Continuing treatment

To make continuing applications for treatment with lenalidomide call the PBS Complex Drugs Programs enquiry line.

Pomalidomide

Initial treatment

Patients receiving pomalidomide under this PBS listing must be registered in the i-access risk management program. Read more on the Celgene website or call Celgene on 1800 235 436.

Make all initial applications for authority approval to prescribe pomalidomide for the treatment of multiple myeloma in writing and:

Initial applications must include the completed:

Continuing treatment

To make continuing applications for treatment with pomalidomide for patients who don't have progressive disease, call the PBS Complex Drugs Programs enquiry line.

Further information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 1 August 2018